Skip to content

A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty

A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02208271
Enrollment
174
Registered
2014-08-05
Start date
2014-08-04
Completion date
2020-08-12
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Failure of Total Hip

Keywords

tissue necrosis, metal on metal total hip, biomarker

Brief summary

The purpose of the study is to develop a biomarker assay to be used as a diagnostic tool for adverse local tissue reaction, or tissue necrosis, in a metal on metal total hip replacement. A convenience sample of a total of 100 hip patients will be enrolled: 50 metal-on-metal revision hips, 25 metal-on-poly revision hips, and 25 pre-operative total hips (no implant, control group) will be enrolled. Preoperative blood serum samples and intraoperative synovial fluid will be obtained from all hips and used for biomarker testing. Additionally, intraoperative assessment of tissue necrosis will be assessed.

Detailed description

Well-functioning MoM implants have shown an increase in serum cobalt and chromium (CoCr) ion levels from the metal debris generated from the implant wear.However, the current evidence suggests that measuring ion levels is unreliable and that increasing ion levels do not correlate with tissue damage. In addition to measuring blood and synovial fluid metal ion levels, ultrasound and MRI with metal artifact reduction sequences (MARS) have been utilized to assess periarticular reactions secondary to metal wear debris. Despite metal reduction software these scans are frequently difficult to interpret. While each of these tests has merit, at the present time there is no single diagnostic test available which delineates the key issue that demands urgent surgical intervention, i.e. tissue necrosis. It is important to have a reliable test to guide surgeons and patients in the shared decision-making process of when surgical intervention is necessary to prevent disabling tissue damage. For this reason, the current study proposes an examination of preoperative serum samples of subjects in addition to synovial fluid collected during revision surgery for biomarkers that may indicate tissue necrosis. To maximize the chance of success of identifying serum biomarkers, all samples will be analyzed using multianalyte assay, biomarker tests. The purpose of the study is to develop a biomarker assay to be used as a diagnostic tool for adverse local tissue reaction, or tissue necrosis, in a metal on metal total hip replacement. A convenience sample of a total of 100 hip patients will be enrolled: 50 metal-on-metal revision hips, 25 metal-on-poly revision hips, and 25 pre-operative total hips (no implant, control group) will be enrolled. Preoperative blood serum samples and intraoperative synovial fluid will be obtained from all hips and used for biomarker testing. Additionally, intraoperative assessment of tissue necrosis will be assessed.

Interventions

None listed

Sponsors

OrthoCarolina Research Institute, Inc.
Lead SponsorOTHER
Charlotte Orthopedic Hospital
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients presenting for a metal on metal hip revision who have cobalt and chromium metal ion levels tested within 6 months of the date of the planned revision surgery. * Patients presenting for a metal on poly hip revision * Revision hip patients must be greater than one year postoperative * The diagnosis at the time of the index, or primary, hip replacement was osteoarthritis. * Patients who have hip osteoarthritis but have not had a total hip surgery (control)

Exclusion criteria

* Patients presenting for a metal on metal hip revision who have cobalt and chromium metal ion levels tested \>6 months of the date of the planned revision * Patients with a total hip on the contralateral side. * Patients with a prior history of periprosthetic infection * Revision cases where the diagnosis at the time of the index, or primary, hip replacement was not osteoarthritis. * Prisoners * Patients not willing to consent for the proposed treatment * Patients with an altered mental status * Active, concurrent metastatic infection * Active, superficial infection * Patients presenting for a metal on poly hip revision to treat trunionosis

Design outcomes

Primary

MeasureTime frameDescription
The number of patients with serum and synovial fluid biomarkersparticipants will be followed for the duration of their hospital stay, an expected average of 2 hoursBlood Serum and Synovial fluid will be tested using a multi-analyte assay test

Secondary

MeasureTime frameDescription
The number of patients with tissue necrosisparticipants will be followed for the duration of their hospital stay, an expected average of 2 hoursTissue necrosis will be assessed during total hip surgery. Tissue necrosis will be scored in subsets including: intraoperative tissue damage, histological necrosis score, histologic ALVAL score, inflammatory infiltrate, and tissue organization

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORThomas Fehring, MD

OrthoCarolina Research Institute, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026